ALXN:NGS-Alexion Pharmaceuticals Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 117.05

Change

0.00 (0.00)%

Market Cap

USD 26.11B

Volume

2.53M

Average Target Price

USD 163.22 (39.44%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Alexion Pharmaceuticals Inc is a biopharmaceutical company engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Company Website : http://www.alexionpharm.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

N/A

 USD 129.92B
GILD Gilead Sciences Inc.

N/A

 USD 89.49B
BIIB Biogen Inc.

N/A

 USD 67.98B
CELG Celgene Corporation

N/A

 USD 60.41B
SHPG Shire plc

N/A

 USD 54.84B
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD 49.76B
REGN Regeneron Pharmaceuticals Inc.

N/A

 USD 45.33B
BMRN BioMarin Pharmaceutical Inc.

N/A

 USD 17.39B
INCY Incyte Corporation

N/A

 USD 16.69B
GRFS Grifols S.A.

N/A

 USD 13.24B

ETFs Containing ALXN

FMDG Fieldstone Merlin Dynamic.. 4.62 % 0.80 %

N/A

 N/A
IBB iShares Nasdaq Biotechnol.. 3.30 % 0.47 %

N/A

 USD 8.27B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.22% 65% D 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.22% 65% D 82% B-
Trailing 12 Months  
Capital Gain -3.30% 71% C- 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.30% 71% C- 61% D-
Trailing 5 Years  
Capital Gain -17.91% 61% D- 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.91% 60% D- 32% F
Average Annual (5 Year Horizon)  
Capital Gain -7.03% 35% F 20% F
Dividend Return -7.03% 35% F 19% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 15.31% 93% A 75% C
Risk Adjusted Return -45.90% 23% F 13% F
Market Capitalization 26.24B 99% A+ 98% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 169.64 1% F 2% F
Price/Book Ratio 2.98 45% F 33% F
Price / Cash Flow Ratio 10.92 3% F 6% F
Price/Free Cash Flow Ratio 76.01 2% F 5% F
Management Effectiveness  
Return on Equity 1.70% 85% B 45% F
Return on Invested Capital 11.12% 89% B+ 72% C-
Return on Assets 1.11% 92% A- 59% F
Debt to Equity Ratio 31.50% 36% F 58% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.